Oumi is initially launching as an open-source repository under an Apache 2.0 license. Developers can use it for research and commercial purposes. Though Oumi does not currently offer a hosted version ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Google’s AI research lab DeepMind has achieved a new leap forward relative to other AI video generation models that are ...

"Here's a lil reminder that people post what they want you to see, whether that's a more flattering angle or cutting out the parts that they don't want you to see," she posted as part of her ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...